PL3487505T3 - Podawanie i dawkowanie diaminofenotiazyn - Google Patents

Podawanie i dawkowanie diaminofenotiazyn

Info

Publication number
PL3487505T3
PL3487505T3 PL17743330.7T PL17743330T PL3487505T3 PL 3487505 T3 PL3487505 T3 PL 3487505T3 PL 17743330 T PL17743330 T PL 17743330T PL 3487505 T3 PL3487505 T3 PL 3487505T3
Authority
PL
Poland
Prior art keywords
diaminophenothiazines
dosage
administration
Prior art date
Application number
PL17743330.7T
Other languages
English (en)
Inventor
Claude Michel Wischik
Björn Olaf SCHELTER
Damon Jude Wischik
John Mervyn David Storey
Original Assignee
Wista Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59399428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3487505(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1612863.9A external-priority patent/GB201612863D0/en
Priority claimed from GBGB1710382.1A external-priority patent/GB201710382D0/en
Application filed by Wista Laboratories Ltd. filed Critical Wista Laboratories Ltd.
Publication of PL3487505T3 publication Critical patent/PL3487505T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/20Agglomerating; Granulating; Tabletting
    • A23P10/28Tabletting; Making food bars by compression of a dry powdered mixture
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/30Encapsulation of particles, e.g. foodstuff additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00Decoration means, markings, information elements, contents indicators
    • B65D2203/02Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Mechanical Engineering (AREA)
  • Botany (AREA)
  • Composite Materials (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
PL17743330.7T 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn PL3487505T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612863.9A GB201612863D0 (en) 2016-07-25 2016-07-25 Administration and dosage of diaminophenothiazines
GBGB1710382.1A GB201710382D0 (en) 2017-06-29 2017-06-29 Administration and dosage of Diaminophenothiazines
PCT/EP2017/068749 WO2018019823A1 (en) 2016-07-25 2017-07-25 Administration and dosage of diaminophenothiazines

Publications (1)

Publication Number Publication Date
PL3487505T3 true PL3487505T3 (pl) 2023-10-09

Family

ID=59399428

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17743330.7T PL3487505T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn
PL23212899.1T PL4335517T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL23212899.1T PL4335517T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn

Country Status (18)

Country Link
US (5) US11065256B2 (pl)
EP (3) EP4335517B8 (pl)
JP (1) JP7073330B2 (pl)
KR (4) KR102475825B1 (pl)
CN (2) CN116531386A (pl)
AU (3) AU2017301966B2 (pl)
CA (1) CA3031578C (pl)
DK (2) DK4335517T3 (pl)
ES (2) ES3046673T3 (pl)
FI (2) FI3487505T3 (pl)
HR (2) HRP20230628T1 (pl)
MX (2) MX385594B (pl)
MY (2) MY201804A (pl)
PL (2) PL3487505T3 (pl)
PT (2) PT4335517T (pl)
SG (1) SG11201900228YA (pl)
SI (2) SI4335517T1 (pl)
WO (1) WO2018019823A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148145A (en) 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
JP7073330B2 (ja) 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
EP3847664A1 (en) 2018-09-05 2021-07-14 Genting Taurx Diagnostic Centre SDN BHD Network methods for neurodegenerative diseases
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) * 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
MX2022013884A (es) * 2020-05-05 2022-11-30 Wista Lab Ltd Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia.
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
EP4590306A1 (en) 2022-09-21 2025-07-30 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
PT1509232E (pt) 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
SI2322517T1 (sl) 2004-09-23 2019-06-28 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)
SI2004155T1 (en) * 2006-03-29 2018-05-31 Wista Laboratories Ltd. Inhibitors of protein aggregation
WO2007110630A1 (en) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
MY148145A (en) 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
JP5918136B2 (ja) 2009-09-24 2016-05-18 ウィスタ ラボラトリーズ リミテッド プロセス
MX355627B (es) 2009-09-24 2018-04-25 Wista Lab Ltd Clorhidratos de metiltioninio (azul de metileno) cristalinos.
DE102010062810B4 (de) 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
JP6093707B2 (ja) 2010-11-30 2017-03-08 ウィスタ ラボラトリーズ リミテッド 化合物製剤
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions

Also Published As

Publication number Publication date
SI3487505T1 (sl) 2023-10-30
PT4335517T (pt) 2025-10-07
PT3487505T (pt) 2023-06-07
MY201804A (en) 2024-03-19
WO2018019823A1 (en) 2018-02-01
EP4335517A3 (en) 2024-08-07
HRP20230628T1 (hr) 2023-09-29
FI3487505T3 (fi) 2023-06-05
ES3046673T3 (en) 2025-12-02
PL4335517T3 (pl) 2026-02-16
CA3031578C (en) 2025-07-08
KR20230058533A (ko) 2023-05-03
KR102475825B1 (ko) 2022-12-08
AU2023203084B2 (en) 2025-03-06
US20250262219A1 (en) 2025-08-21
CA3031578A1 (en) 2018-02-01
US20230346794A1 (en) 2023-11-02
CN116531386A (zh) 2023-08-04
SI4335517T1 (sl) 2025-11-28
MX2019000946A (es) 2019-05-13
FI4335517T3 (fi) 2025-10-21
CN109789148A (zh) 2019-05-21
KR20240074909A (ko) 2024-05-28
EP3487505B1 (en) 2023-05-03
US20200016165A1 (en) 2020-01-16
AU2023203084A1 (en) 2023-06-08
US20220008431A1 (en) 2022-01-13
HRP20251365T1 (hr) 2025-12-19
US20230165877A1 (en) 2023-06-01
AU2022291420B2 (en) 2024-05-09
KR102592614B1 (ko) 2023-10-24
US12310973B2 (en) 2025-05-27
EP4335517B8 (en) 2025-10-22
EP4223297A2 (en) 2023-08-09
EP3487505A1 (en) 2019-05-29
JP2019527216A (ja) 2019-09-26
KR20190031552A (ko) 2019-03-26
EP4335517A2 (en) 2024-03-13
ES2946165T3 (es) 2023-07-13
EP4223297A3 (en) 2023-11-15
DK4335517T3 (da) 2025-09-29
US12128051B2 (en) 2024-10-29
AU2022291420A1 (en) 2023-02-02
MX2021009899A (es) 2021-09-14
EP4335517B1 (en) 2025-08-27
US11759469B2 (en) 2023-09-19
MX385594B (es) 2025-03-18
WO2018019823A8 (en) 2018-04-05
MY210565A (en) 2025-09-30
US11065256B2 (en) 2021-07-20
DK3487505T3 (da) 2023-05-30
AU2017301966B2 (en) 2022-09-22
KR20230003261A (ko) 2023-01-05
SG11201900228YA (en) 2019-02-27
AU2017301966A1 (en) 2019-03-07
JP7073330B2 (ja) 2022-05-23

Similar Documents

Publication Publication Date Title
ZA202102219B (en) Dosage and administration of non-fucosylated anti-cd40 antibodies
PT4335517T (pt) Administração e dosagem de diaminofenotiazinas
IL287749A (en) Compositions for administering implantable drugs and methods of their use
IL251834B1 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
GB201817116D0 (en) Pharmaceutical preparation of palbociclic and preparation method thereof
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
GB201406172D0 (en) Therapy and pharmaceutical composition
IL253791A0 (en) Doses and methods of administration of telavancin
PT3503885T (pt) Composição farmacêutica e métodos de utilização
IL252080A0 (en) Oral administration of drugs that are unstable or poorly absorbed
ZA201902085B (en) Medicinal use of serrulatane diterpenes
PL3328385T3 (pl) Postać dawkowania leku alkaloidu barwinka
GB201519644D0 (en) Therapy and pharmaceutical composition
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
GB201710382D0 (en) Administration and dosage of Diaminophenothiazines
GB201718320D0 (en) Therapeutic substances and their preparation